IBIO, INC. Cost of Revenue
IBIO, INC. (IBIO) reported Cost of Revenue of $216.00 thousand for the 12-month period ending 2022-06-30, per its 10-K filed 2022-10-11.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2022-10-11
- IBIO, INC. cost of goods and services sold for the quarter ending 2022-06-30 was $15.00K, a 91.98% decline year-over-year.
- IBIO, INC. cost of goods and services sold for the quarter ending 2022-03-31 was $48.00K, a 90.26% decline year-over-year.
- IBIO, INC. cost of goods and services sold for the quarter ending 2021-12-31 was $113.00K, a 46.45% decline year-over-year.
- IBIO, INC. cost of goods and services sold for the quarter ending 2021-09-30 was $40.00K, a 62.62% decline year-over-year.
- IBIO, INC. cost of goods and services sold for fiscal 2022 was $216.00K, a 85.23% decline from fiscal 2021.
- IBIO, INC. cost of goods and services sold for fiscal 2021 was $1.46M, a 107.97% increase from fiscal 2020.
- IBIO, INC. cost of goods and services sold for fiscal 2020 was $703.00K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2022-06-30 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-11 | $63.00K derived: sum of 2 quarters · filed 2022-10-11 | $176.00K derived: sum of 3 quarters · filed 2022-10-11 | $216.00K 10-K · filed 2022-10-11 |
| 2022-03-31 | $48.00K 10-Q · filed 2022-05-12 | $161.00K derived: sum of 2 quarters · filed 2022-05-12 | $201.00K 10-Q · filed 2022-05-12 | $388.00K derived: sum of 4 quarters · filed 2022-10-11 |
| 2021-12-31 | $113.00K 10-Q · filed 2022-02-14 | $153.00K 10-Q · filed 2022-02-14 | $340.00K derived: sum of 3 quarters · filed 2022-10-11 | $833.00K derived: sum of 4 quarters · filed 2022-10-11 |
| 2021-09-30 | $40.00K 10-Q · filed 2021-11-15 | $227.00K derived: sum of 2 quarters · filed 2022-10-11 | $720.00K derived: sum of 3 quarters · filed 2022-10-11 | $931.00K derived: sum of 4 quarters · filed 2022-10-11 |
| 2021-06-30 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-11 | $680.00K derived: sum of 2 quarters · filed 2022-10-11 | $891.00K derived: sum of 3 quarters · filed 2022-10-11 | $1.46M 10-K · filed 2022-10-11 |
| 2021-03-31 | $493.00K 10-Q · filed 2022-05-12 | $704.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.27M 10-Q · filed 2022-05-12 | $1.11M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $211.00K 10-Q · filed 2022-02-14 | $318.00K 10-Q · filed 2022-02-14 | $617.00K derived: sum of 3 quarters · filed 2022-02-14 | $703.00K derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $107.00K 10-Q · filed 2021-11-15 | $406.00K derived: sum of 2 quarters · filed 2021-11-15 | $492.00K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $299.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $385.00K derived: sum of 2 quarters · filed 2021-09-28 | $703.00K 10-K · filed 2021-09-28 | |
| 2020-03-31 | $86.00K 10-Q · filed 2021-05-17 | $404.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |